Abivax
ABVX
247 hedge funds and large institutions have $7.61B invested in Abivax in 2025 Q4 according to their latest regulatory filings, with 107 funds opening new positions, 76 increasing their positions, 50 reducing their positions, and 24 closing their positions.
346% more first-time investments, than exits
New positions opened: 107 | Existing positions closed: 24
73% more capital invested
Capital invested by funds: $4.41B → $7.61B (+$3.2B)
62% more funds holding in top 10
Funds holding in top 10: 21 → 34 (+13)
52% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 50
50% more funds holding
Funds holding: 165 → 247 (+82)
50% more call options, than puts
Call options by funds: $341M | Put options by funds: $228M
3.49% more ownership
Funds ownership: 68.76% → 72.25% (+3.5%)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$183M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$110M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$98.2M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$83.5M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$78.6M |
Top Sellers
ABVX Hedge Fund Activity: Q4 2025 in Review
247 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Abivax (ABVX) for Q4 2025, worth a combined $7.61B — up 73% from $4.41B a quarter earlier.
Buyers outnumbered sellers: 107 funds opened new ABVX positions and 24 closed out — a net gain of 83 holders — while 76 added to existing stakes and 50 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $183M. The largest seller was Cormorant Asset Management, cutting an estimated $65.5M.
- 247 institutional investors held Abivax (ABVX) as of Q4 2025, up from 165 in Q3 2025.
- Funds reported $7.61B of Abivax stock for Q4 2025, up 73% quarter-over-quarter.
- 107 funds opened new Abivax positions in Q4 2025 and 24 closed out, a net change of +83 holders.
- The largest Abivax buyer in Q4 2025 was Morgan Stanley, an estimated $183M added.
- The largest Abivax seller in Q4 2025 was Cormorant Asset Management, an estimated $65.5M sold.
Based on aggregated 13F filings for Q4 2025.